Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 27;8(8):ofab338.
doi: 10.1093/ofid/ofab338. eCollection 2021 Aug.

Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts

Anne K Monroe  1 , Matthew E Levy  2 , Alan E Greenberg  1 , Jeanne C Keruly  3 , Richard D Moore  3 , Michael A Horberg  4 , Paige Kulie  1 , Bernadine S Mohanraj  5 , Princy N Kumar  5 , Amanda D Castel  1 ; DC Cohort Executive Committee
Collaborators, Affiliations

Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts

Anne K Monroe et al. Open Forum Infect Dis. .

Abstract

Integrase inhibitors (INSTIs) are recommended by expert panels as initial therapy for people with HIV. Because there can be disparities in prescribing and uptake of novel and/or recommended therapies, this analysis assessed potential INSTI prescribing disparities using a combined data set from the Johns Hopkins HIV Clinical Cohort and the DC Cohort. We performed multivariable logistic regression to identify factors associated with ever being prescribed an INSTI. Disparities were noted, including clinic location, age, and being transgender. Identifying disparities may allow clinicians to focus their attention on these individuals and ensure that therapy decisions are grounded in valid clinical reasons.

Keywords: HIV; cohort; disparities; integrase strand transfer inhibitors (INSTIs); transgender.

PubMed Disclaimer

References

    1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – a Working Group of the Office of AIDS Research Advisory Council (OARAC ). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2018. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Ad.... Accessed 11 January 2021.
    1. Mills AM, Brunet L, Fusco JS, et al. . Virologic outcomes among ART-naïve individuals initiating dolutegravir, elvitegravir, raltegravir or darunavir: an observational study. Infect Dis Ther 2020; 9:41–52. - PMC - PubMed
    1. Brehm TT, Franz M, Hüfner A, et al. . Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients. Medicine (Baltimore). 2019; 98:e16721. - PMC - PubMed
    1. Molina JM, Clotet B, van Lunzen J, et al. . Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV 2015; 2:e127–36. - PubMed
    1. Davy-Mendez T, Napravnik S, Zakharova O, et al. . Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting. AIDS 2019; 33:1187–95. - PMC - PubMed

LinkOut - more resources